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Abstract
Hirschsprung disease (HSCR, OMIM 142623) involves congenital intestinal obstruction
caused by dysfunction of neural crest cells and their progeny during enteric nervous system
(ENS) development. HSCR is a multifactorial disorder; pathogenetic variants accounting for
disease phenotype are identified only in a minority of cases, and the identification of novel
disease-relevant genes remains challenging. In order to identify and to validate a potential
disease-causing relevance of novel HSCR candidate genes, we established a complemen-
tary study approach, combining whole exome sequencing (WES) with transcriptome analy-
sis of murine embryonic ENS-related tissues, literature and database searches, in silico
network analyses, and functional readouts using candidate gene-specific genome-edited
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cell clones. WES datasets of two patients with HSCR and their non-affected parents were
analysed, and four novel HSCR candidate genes could be identified: ATP7A, SREBF1,
ABCD1 and PIAS2. Further rare variants in these genes were identified in additional HSCR
patients, suggesting disease relevance. Transcriptomics revealed that these genes are
expressed in embryonic and fetal gastrointestinal tissues. Knockout of these genes in neu-
ronal cells demonstrated impaired cell differentiation, proliferation and/or survival. Our
approach identified and validated candidate HSCR genes and provided further insight into
the underlying pathomechanisms of HSCR.
Author summary
Hirschsprung disease (HSCR) is a rare developmental disorder. It leads to the absence of
enteric nerve cells (aganglionosis) in the large intestine and is caused by functional defects
of neuronal precursor cells during embryonic development of the gut nervous system.
The aganglionosis manifests as a variety of symptoms including impaired peristalsis and
the formation of a pathogenic dilatation of the intestine (megacolon). The etiology of
HSCR is considered to be multifactorial. Variants in more than 20 genes have been
reported to be overrepresented in HSCR and replicated in independent cohorts. However,
variants in those risk genes account for only 30% of all cases, suggesting that many more
genes have to be implicated in the development of HSCR. As the identification and the
subsequent validation of novel gene variants to be disease-causing or not, still remains a
major challenge, we established and applied a complementary study pipeline. This enabled
us to identify four novel candidate genes in two HSCR patients and to validate their
potential disease relevance. Our approach represents a suitable way to dissect the complex
genetic architecture underlying HSCR.
Introduction
The neurocristopathy Hirschsprung disease (HSCR, OMIM 142623), also termed congenital
intestinal aganglionosis, represents one of the main causes for neonatal intestinal obstruction.
It is characterized by the absence of enteric ganglia (aganglionosis) in the distal bowel.
Depending on the length of the affected segment, it is categorized as short-segment (S-HSCR;
up to 80%), long-segment (L-HSCR; up to 20%), or total colonic aganglionosis (TCA; up to
8%). The diagnosis is often made within the first days after birth when meconium passage is
delayed or a megacolon forms. Patients can also suffer from enterocolitis, constipation,
abdominal pain, or emesis. So far, the only treatment is to surgically resect the affected agan-
glionic bowel segment [1–3].
The enteric nervous system (ENS) innervates the gastrointestinal (GI) tract, regulating
blood flow, gut motility, peristalsis, ion and fluid homeostasis, and secretion of signaling medi-
ators [4,5]. The ENS originates from vagal neural crest cells (NCCs) during embryonic devel-
opment, with delamination between E8.5 and E9.5 in mice and before week 4 of gestation in
humans [3,4]. NCC-derived progenitor cells that invade and colonize the developing gut are
enteric neural crest-derived cells (ENCDCs). They give rise to enteric neurons and glia cells,
which are organized into the submucosal and myenteric plexus ganglia [4,6,7]. Impaired
migration, proliferation, survival, or differentiation of NCCs or ENCDCs in the developing
lower GI tract may cause the enteric neuropathy HSCR [5,7].
Genetically, HSCR is a rare, multifactorial disorder with an incidence of 1:5,000 live births,
showing male sex preponderance, incomplete penetrance, and variable expressivity [1,8,9]. To
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date, more than 20 genes have been identified and replicated that affect signaling cascades cru-
cial for ENS development. The major susceptibility locus is RET as mutations account for up
to 50% of familial and 20% of sporadic HSCR cases. To date, mutations in other HSCR risk
genes have been identified in about 5% of patients [9,10]. However, variants in these estab-
lished genes account for only 30% of patients, but many more genes have been implicated in
its pathoetiology [9,11]. Identifying disease-relevant variants remains a major challenge.
In the present study, we used an evidence-based procedure to select HSCR candidate genes
identified by whole exome sequencing (WES). To prioritize and validate candidate genes, we
evaluated bioinformatically filtered WES data based on literature and database searches, and on
expression analyses of embryonic ENS tissues. To accumulate further evidence for the potential
disease-relevance of our selected candidate genes, WES datasets of further HSCR patients as well
as of individuals presenting mostly with a neurological phenotype were taken into account, allow-
ing the identification of further rare variants. Candidate genes were functionally analyzed using
gene-specific CRISPR/Cas9-based knockout (KO) cell clones. We focused on properties relevant
to HSCR pathoetiology, such as migration, proliferation, cell survival, and differentiation.
Our approach effectively and comprehensively evaluated novel candidate HSCR genes and
may serve as a blueprint for prospective studies aiming to discover and validate novel disease-
causing HSCR genes.
Results
Candidate gene identification and selection
Coding variants of two sporadic L-HSCR patients and their non-affected parents were assessed
by trio WES. Bioinformatic filtering identified 369 potential disease-causing, rare, coding,
non-synonymous SNVs and indels in 357 genes for patient I and 373 in 356 genes for patient
II (Fig 1A, S1 Fig). Obtained variants were filtered based on the disease model (including de
novo for autosomal dominant, homozygous or compound heterozygous for autosomal reces-
sive, and hemizygous for X-linked), resulting in 16 candidate variants in 11 genes for patient I
and 19 candidate variants in 14 genes for patient II (Fig 1A, S1 Table, S2 Table, S1 Fig). Of
note, none of the filtered candidates were known HSCR genes. However, targeted screening
for ENS-relevant and HSCR risk genes (S3 Table) revealed three heterozygous variants for
patient I (ECE1 (rs141146885), SERPINI1 (rs61750375), and SUFU (rs34135067)) and one het-
erozygous variant for patient II (EDNRB (rs780841273)).
To validate this in silico selection and to investigate, whether remaining candidate genes are
expressed in disease-relevant stages and tissues, transcriptional profiles of three murine
embryonic ENS-relevant tissues (E8.75 and E9.5 vagal NCCs, and E13.5 gut) were assessed
(Fig 1B). Besides the expression of murine gene orthologues of already confirmed HSCR genes
(Ret, Gdnf, Gfra1, Ednrb, Edn3, Ece1, Sox10, Phox2b, Sema3a, Sema3b, Sema3c, Dnmt3b, Nrtn,
Pspn, Ntf3, Nrk3, L1cam, Kiaa1279, Zeb2, Tcf4, Prok1, Prokr1, Prokr2, Nrg1, Nrg3) [10] (Fig
1C), comparable expression levels could also be detected for murine gene orthologues of our
selected candidate genes (9/11 for patient I, 11/14 for patient II) (Fig 1C' and 1C"). The
obtained results verified our selection, as orthologues of candidates were all expressed at
embryonic stages and tissues relevant for disease manifestation (S1 Fig).
Prioritization of novel HSCR candidate genes
Literature and database searches were performed to prioritize candidate genes. Further, genes
presenting with variants of CADD scores above 13 were taken into account, which indicate
that the variant is among the 5% most deleterious substitutions in the human genome [12]. 14
out of 16 variants of patient I as well as 16 out of 19 variants of patient II reached this CADD
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score threshold (S1 Table, S2 Table). Moreover, we considered central nervous system (CNS)
phenotypes, finally leading to 4 candidates in patient I and 9 candidates in patient II (S1 Table,
S2 Table, S1 Fig).
In the filtered list of candidate genes, two genes per patient were prioritized for detailed charac-
terization, and variants were confirmed by Sanger sequencing: ATP7A (ATPase COPPER TRANS-
PORTINGALPHA) and SREBF1 (STEROL REGULATORY ELEMENT-BINDING PROTEIN 1)
for patient I, and ABCD1 (ATP-BINDING CASSETTE SUBFAMILY DMEMBER 1) and PIAS2
(PROTEIN INHIBITOROF ACTIVATED STAT 2) for patient II (S1 Table, S2 Table, S2 Fig).
Genetic evaluation
Moreover, screening of WES datasets for all four candidate genes of 767 HSCR patients
revealed additional rare variants, although the variants present in patients I and II were not
seen. Based on our filtering criteria, 6 non-synonymous variants for ATP7A, 10 for SREBF1, 2
and 5 for ABCD1 and PIAS2 respectively could be found (Fig 2A–2D, S4 Table, S1 Fig).
Candidate gene validation
IPA network analysis. To better understand the biological context of selected candidates,
we performed a network analysis using the IPA software tool. All four candidates showed mul-
tiple direct and indirect protein interactions with ENS-relevant and HSCR risk factors (Fig
2E). ATP7A is indirectly connected to RBP4 via the LDL complex. The very long chain fatty
Fig 1. WES data and microarray analysis. (A) Whole exome sequencing (WES) of two sporadic L-HSCR cases in a trio design was followed by variant calling to
identify putative HSCR candidate genes. After filtering for respective mutation types, 11 candidate genes remained for patient I and 14 for patient II. (B) For expression
validation of filtered candidate genes, transcriptional profiles of relevant embryonic murine tissues were assessed by microarray analysis: vagal NCCs at E8.75/E9.5,
embryonic gut at E13.5. (C, C', C") Microarray analyses of embryonic murine tissue showing mRNA expression values of known HSCR risk genes (C), and candidate
gene homologs of patient I (C') and patient II (C") (selected candidates for follow-up analyses are underscored) (C, C', C": n = 3, mean + standard error of mean (SEM)).
Fig 1B modified from: https://www.hhmi.org/content/zhang-yi-research-abstract-slideshow. MAF: minor allele frequency, NCC: neural crest cell.
https://doi.org/10.1371/journal.pgen.1009106.g001
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Fig 2. Genetic evaluation of candidate genes and network analyses. (A-D) Disease relevance of all candidate genes was examined by evaluating genetic data from
additional patients with HSCR. Variants shown in red were detected in index cases of this study while filtered variants from other cohorts are shown in black (# variant
was found in both). More information about the filtered rare variants is given in S4 Table. Protein domain structures and the localization of filtered rare variants are
given for ATP7A (A), SREBF1b (B), ABCD1 (C), and PIAS2ß (D). Functional domains in specific isoforms were annotated based on database entries (Pfam, NCBI,
Uniprot) or additional literature findings [53,54]. HMA: heavy metal associated, TM: transmembrane, A: actuator, N: nucleotide, P: phosphorylation, HLH: helix loop
helix, LMNA: LAMIN A/C, ABC: ATP-binding cassette, SAP: scaffold attachment factor-A/B, acinus and PIAS, PINIT: Pro-Ile-Asn-Ile-Thr, Zn-SP-RING: zinc binding
—Siz/Pias—really interesting new gene, SUMO: small ubiquitin-related modifier, NLS: nuclear localization signal. (E) IPA core analysis was performed using lists of
filtered variants detected in both index cases (S1 and S2 Tables), of ENS-relevant and known HSCR risk factors (S3 Table). Indirect interactions were only kept if linked
to candidate gene products. ENS-relevant factors are highlighted in green while validated HSCR risk factors are lettered in red. Candidates are colored in yellow, the four
selected most promising candidates are marked by red lettering. Protein interactions between candidates and factors of interest are marked in red. Proteins are arranged
according to their subcellular localization.
https://doi.org/10.1371/journal.pgen.1009106.g002
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acid (VLCFA) transporter ABCD1 is directly connected to the HSCR factor DNMT3B, while
several direct connections for SREBF1 and PIAS2 were found. Among others, both candidates
are directly connected to the HSCR-associated factor NAV2. Additionally, PIAS2 was identi-
fied as a SUMOylation mediator of PTEN (Fig 2E, S1 Fig).
Screening of additional WES and WGS data. To investigate, whether our selected candi-
dates might be involved in ENS- and CNS-related phenotypes alike, we subsequently applied
the same search and filtering strategy to a set of approximately 15,500 cases submitted for clini-
cal WES and WGS (S1 Fig). This cohort is clinically diverse, with a majority of cases being sub-
mitted for neurological indications. In total, we identified 114 individuals harboring coding
non-synonymous or indel variants in one of our four selected candidate genes. Of these, 37
individuals carried variants in ATP7A, 31 in SREBF1, 33 in ABCD1 and 13 in PIAS2. Investiga-
tion of the clinical indications listed by the referring provider showed that 101 out of 114 cases
presented with a GI phenotype (ATP7A: 30; SREBF1: 30; ABCD1: 28; PIAS2: 13). Furthermore,
11 individuals had autism spectrum disorder (ASD) listed as a clinical indication (ATP7A: 4;
SREBF1: 3; ABCD1: 2; PIAS2: 2), and 28 individuals were diagnosed with intellectual disability
(ATP7A: 9; SREBF1: 3; ABCD1: 14; PIAS2: 2) (S5 Table).
GTEx database analysis. In line with this, we also considered expression data in the
GTEx database (human brain, colon tissue) to verify their relevance in the brain and the gut
and could detect a positive expression in both tissues (S7 Table, S1 Fig).
Expression analyses in murine and human tissues. Immunofluorescence analyses of
murine embryos at relevant developmental stages (E9.5, E10.5, E11.5, E13.5) was performed
and revealed broad protein expression of all candidates in ENS-related tissue structures and
cells (S6 Table, S3A Fig, S3B Fig). Complementary, immunohistochemical analysis also
showed candidate gene expression in human fetal colon sections at 25th week of gestation
(S3C Fig). Candidate gene expression was also confirmed in human fetal hindgut specimens at
12, 14, and 16 weeks of gestation in published data (S4 Fig) [13].
All validation steps are summarized in S7 Table.
Determining the neuronal-specific role of candidates
Generation of gene-specific KO clones. To determine the neuronal functions of selected
genes, we generated gene-specific KO cell clones of the human neuroblastoma cell line
SHSY5Y. The differentiation, migration, proliferation, and survival of these cells were assessed.
A KO clone of the major HSCR gene RET was analyzed as a proof-of-principle control, and all
clones were also compared with a mock control clone.
KO clones either harbored homozygous (RET KO, ABCD1 KO) or compound heterozygous
genome modifications (ATP7A KO, SREBF1 KO) (S5 Fig). Off-target effects were largely excluded
(S1 Data). However, genome editing did not work for PIAS2 as no KO clone with neuronal mor-
phology could be generated, despite several attempts with sgRNAs targeting two different exons.
While the genetically modified exon 6 harboring a homozygous one-nucleotide insertion escaped
KO by alternative splicing, sgRNAs targeting exon 2 did not yield a suitable clone.
Neuronal differentiation of KO clones. KO clones were differentiated into a neuronal-
like phenotype to investigate the functional impact of candidate genes on neuronal develop-
ment (KO vs mock control).
All four KO clones showed impaired development of a neuronal-like phenotype (Fig 3A).
The neuronal morphology (elongated cell bodies carrying several neurite-like outgrowths)
became apparent from the undifferentiated to the 7d differentiated state in all clones, except
for the ATP7A KO clone, where a confluent cell monolayer was present after 7d (Fig 3A"').
After 7+14d, only the mock control clone had a highly organized network of interconnected
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neuronal-like clusters (Fig 3A'). KO clones for RET (Fig 3A"), SREBF1 (Fig 3A""), and ABCD1
(Fig 3A""') showed delayed network formation. After 7+28d, all genome-edited clones (Fig
3A), except the ATP7A KO clone (Fig 3A"'), showed neuronal-like clusters, which were con-
nected by semi-adherent neurite-like connections.
Throughout differentiation, mRNA expression profiles of various cell type markers were
assessed (Fig 3B, S6 Fig). Expression of these markers increased in the mock control clone with
advancing neuronal-like maturation. While MAP2, TAU, and SYP were only marginally
expressed, TUBB3 and GAP43 were prominently expressed. Marker expression was signifi-
cantly different in all gene-specific KO clones during neuronal differentiation at various differ-
entiation stages. MAP2 and GAP43 expression was significantly reduced at several stages,
while SYP expression was upregulated after 7+21d in the RET KO clone. For the ATP7A KO
clone, TUBB3 and TAU expression was significantly higher than in the undifferentiated con-
trol, but TAU expression dropped over time. At 7+7d, MAP2 and GAP43 expression was
lower. During early differentiation, most markers showed increased expression in the SREBF1
KO clone, except for GAP43 after 7+7d. In contrast, expression of all markers was significantly
higher in the ABCD1 KO clone during later neuronal development (Fig 3B).
In addition, expression of P75NTR and NES (neuronal progenitor markers) and UCHL1
and ASCL1 (pan-neuronal markers) was investigated in all cell clones (S6 Fig). These analyses
are described in detail in the Supplementary (S1 Data).
Complementary immunofluorescence analyses confirmed TUBB3, MAP2, TAU, SYP, and
GAP43 marker expression in most cell clones differentiated for 7+14d (Fig 3C). Additionally,
cellular morphologies were comparable to previous analyses (Fig 3A). Corresponding to their
functions, signals were detectable in all KO clones in neurite-like projections (TUBB3, MAP2,
GAP43 and TAU), while for the synapse-marker SYP, a dotted-like staining pattern was
observed along these structures (Fig 3C). However, for the ATP7A KO clone, no neuronal-like
clusters and no distinct staining pattern for TAU could be detected at this maturation stage
(Fig 3C"'). Numerical raw data for Fig 3B and S6 Fig are given in S13 Table.
Further comparative functional in vitro analyses. Cell migration (Fig 4A), proliferation
(Fig 4B), and survival (Fig 4C) were compared in undifferentiated and differentiated KO
clones and the mock control clone. Cell migration was significantly reduced in the undifferenti-
ated RET KO clone (Fig 4A'), but no difference was observed in differentiated clones (Fig 4A").
In addition, significantly fewer proliferative cells (BrdU+) were detected in the undifferentiated
ABCD1 KO clone (Fig 4B'), whereas no difference was observed in differentiated (7+1d) candi-
date clones (Fig 4B"). Apoptosis was higher in the undifferentiated ABCD1 KO clone (Fig 4C'),
and the differentiated (7+7d) SREBF1 KO clone (Fig 4C"). Respective numerical data are sum-
marized in S13 Table.
Discussion
Identifying and validating disease-relevant genetic variants in complex disorders such as
HSCR remains challenging. To overcome these obstacles, we established a complementary
Fig 3. Differentiation of genome-edited clones on morphological and marker expression level. (A) Genome-edited clones and the mock control
clone were differentiated into a neuronal-like phenotype and cell morphologies were assessed by brightfield microscopy (A': mock control, A": RET
KO, A"': ATP7A KO, A"": SREBF1 KO, A""': ABCD1 KO). Scale bars: 100μm. (B) Gene expression profiles of different neuronal cell fate markers were
assessed in differentiating cell clones (TUBB3, MAP2, TAU, SYP, GAP43) by qRT PCR. (n = 3, mean + standard error of mean (SEM); exploratory
data analysis by two-sided unpaired t-Test with/without Welch’s correction, �p<0.05; �� p<0.01; ��� p< 0.001). (C) Cells after 7+14d of
differentiation were investigated by IF analyses for marker expression patterns. Images are representatives of different experiments. Neuronal-specific
markers are indicated in red (MAP2, GAP43, SYP) and green (TUBB3, TAU) (C': mock control, C": RET KO, C"': ATP7A KO, C"": SREBF1 KO, C""':
ABCD1 KO). Nuclei were counterstained with Hoechst 33342 (blue). Scale bars: 50μm. Undiff: undifferentiated.
https://doi.org/10.1371/journal.pgen.1009106.g003
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approach to select candidate genes, to collect gene-related information on multiple levels, and
finally to determine their disease relevance in functional readouts.
WES data revealed several hundreds of promising HSCR candidate variants in patient I and
II. After prioritizing specific mutation types, we further took mRNA expression profiles in
murine embryonic tissues, CADD scores (�13), published literature, and database informa-
tion into account. We considered extra-intestinal neurological phenotypes to be relevant, since
the CNS and ENS are structurally and functionally similar [4,14–16], and interconnections
between CNS disorders and HSCR/ENS-relevant phenotypes have already been reported
[17,18]. Recently, genes involved in HSCR and ENS development (such as CHD8 [19] and
NLGN3 [20,21]) were also found to be implicated in neurodevelopmental disorders indicating
that genetic neurodevelopmental processes might be conserved between the CNS and ENS. Of
note, there is growing evidence suggesting that variants predisposing to ASD by affecting CNS
structure and function might also impact ENS development culminating in disturbed GI struc-
ture and function [22].
Finally, we ended up with 4 genes for patient I and 9 genes for patient II with potentially rel-
evant variants, that all would equally have qualified for further evaluation. However, since the
envisioned functional part of the pipeline was highly demanding, we decided on two
Fig 4. Comparative functional analyses of all genome-engineered clones. (A) Cell migration in undifferentiated (A') and differentiated (7+1d) (A") cell clones was
measured by Boyden chamber assays. In the positive control, FBS was applied as a chemoattractant for undifferentiated cells and BDNF was applied as a
chemoattractant for differentiated cells (negative: basal medium only). (B) The proliferation capacity of undifferentiated (B') and differentiated (7+1d) (B") genome-
edited clones was assessed by a BrdU assay. (C) The number of apoptotic cells in undifferentiated (C') and differentiated (7+7d) (C") clones was determined by a
TUNEL assay. (A-C) All functional analyses were compared with the mock control clone. Bar plots show mean + standard error of mean (SEM) (n�3). One-way
ANOVA, Bonferroni corrected, �p<0.05; ��p<0.01; ���p< 0.001. Undiff: undifferentiated.
https://doi.org/10.1371/journal.pgen.1009106.g004
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candidates per patient: ATP7A and SREBF1 for patient I and ABCD1 and PIAS2 for patient II.
Having now proven this study pipeline as feasible, it represents a perfect basis for an auto-
mated high-throughput approach. Once established, we aim to apply the adapted pipeline to
additional candidates in the future.
ATP7A encodes a copper transporter which regulates intracellular ion levels and has previ-
ously been implicated in Menkes disease [23]. The VLCFA transporter ABCD1 is involved in
X-linked adrenoleukodystrophy (X-ALD), and impaired ABCD1 function causes substrate
accumulation and neurodegeneration [24]. SREBF1 encodes a crucial regulator of sterol and
cholesterol biosynthesis, while PIAS2 encodes an E3-SUMO ligase and has multiple targets
besides the STAT family [25,26]. These candidates have also been implicated in neurodegener-
ative disorders including Alzheimer and Parkinson disease [27,28].
We validated the disease relevance of our selected candidates using multiple approaches. In
silico network analyses revealed direct and indirect interactions between the candidates and
ENS-/HSCR-relevant factors [29–31], suggesting the selected candidates modify ENS-relevant
genes, or participate in uncharacterized HSCR susceptibility pathways [1,32]. The disease rele-
vance of our candidates was strengthened by additional variants in other HSCR patients.
Importantly, another non-synonymous variant in ATP7A was also found in a patient with
pseudo-obstruction (rs201788154, c.2452A>G, p.T818A), underlining its potential signifi-
cance in functional GI disorders.
As already mentioned, neurodevelopmental processes seem to be conserved between the ENS
and the CNS. Thus, genetic alterations might affect both systems likewise. In order to get an idea,
whether our candidates might be involved in ENS-/CNS-related phenotypes, we screened clinical
WES/WGS data of a non-HSCR, neurodevelopmental disease-focused clinical cohort. Obtained
results are in line with this, as patients carrying variants in the selected candidates presented not
only with neurological phenotypes but also with a high prevalence of GI phenotypes.
We analyzed the protein expression of candidate genes in murine embryonic ENS-relevant
tissues and human fetal colon tissue. Although the human specimens did not match the stages
examined in murine tissue, expression data from human tissue was valuable because HSCR is
a prenatal human disorder. The transcript and protein expression profiles of the four candi-
dates are already known from different species and tissues at various developmental stages
[24,33–37]. However, to the best of our knowledge, ENS-specific analyses have not been per-
formed so far.
To correlate candidate gene function with HSCR-causing pathomechanisms, gene-specific
KO cell clones were generated from SHSY5Y human neuroblastoma cells. Although this CNS-
derived cell source does not mimic the ENS, we hypothesized that neuronal differentiation,
migration, proliferation, and survival are conserved between the CNS and ENS. This assump-
tion is supported by the previous finding that the same genes are involved in ENS and CNS
development. We successfully generated KO clones for ATP7A, SREBF1, ABCD1 and RET, but
PIAS2 escaped all editing approaches. It is tempting to speculate that PIAS2 has an essential
cellular function [38], particularly because the edited neuronal-like clone escaped CRISPR--
Cas9-based KO by alternative splicing and expressed a shorter, unknown PIAS2 isoform.
To assess phenotypic alterations resembling HSCR pathogenesis in vitro, we also studied
neuronal differentiation, migration, proliferation, and survival in KO clones compared with a
mock control and RET KO clone. Most striking phenotypic alterations for the RET KO clone
were shown for its neuronal differentiation and migration capacity. These findings were in
agreement with two previous studies–one using induced pluripotent stem (iPS) cell-derived
ENCDCs from a HSCR patient with a RET mutation and one using neuronal precursors from
Ret-deficient mice [39,40]. In addition, neuronal markers were differentially expressed in the
RET KO clone, underlining the suitability of our in vitro approach in assessing neuronal-
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specific impairments. We did not validate the neuronal markers on the protein level, but the
mRNA expression profiles (e.g. GAP43) were consistent with results from previous studies
[41]. How RET deficiency influences marker expression in the differentiating KO clone and
the functional relevance of this dysregulation should be elucidated in future studies.
Candidate gene-specific KO clones displayed altered cellular functions. The most striking
morphological difference was seen in the ATP7A KO clone, which displayed high cell densities in
line with neuronal-like maturation. Although we did not detect changes in proliferation, the
higher cell densities may have been caused by the inverse relationship between ATP7A expres-
sion and proliferation in neuroblastoma cells [33]. In vivo analyses using a murine disease model
demonstrated that Atp7a might be involved in axonal outgrowth and synaptogenesis [42]. This
may explain the significantly reduced MAP2 and GAP43 expression in differentiating cells.
The SREBF1 KO clone showed altered differentiation and survival compared with the mock
control clone. Srebf1 is involved in lipogenesis, so may be crucial for dendritogenesis [43]. Oth-
ers have shown that Srebf1c KO causes peripheral neuropathy in mice [44] and that SREBF1 is
crucial for cancer cell growth and viability [45,46]. The observed defects in our SREBF1 KO
clone are thus in line with its known protein functions.
Further, ABCD1 deficiency reduced proliferation and increased apoptosis in undifferenti-
ated cells. In contrast, neuronal-like network formation was only slightly altered and mRNA
expression of many neuronal markers was mostly upregulated during differentiation. These
findings may be explained by a compensatory effect of ABCD2 in the KO clone which might
be launched during neuronal cell fate induction [47,48]. In the X-ALD zebrafish abcd1 KO
model, oligodendrocytes showed increased apoptotic rates [36]. We observed a comparable
defect in our neuronal-like ABCD1 KO clone.
Along with the difficulty pinpointing HSCR-relevant candidate genes, the complex patho-
genesis of HSCR is multifactorial [8,10]. To get a complete pathophysiological picture in future
studies, rare coding variants (SNVs) cannot be studied alone; structural alterations (CNVs),
common non-coding risk alleles, and rare coding variants affecting ENS-relevant genes should
also be considered. To further strengthen the importance of our four selected candidate genes
in HSCR, transcriptome analyses and protein analyses in genome-edited cell clones must be
performed. In addition, genome-edited primary ENS-derived cells or patient-derived iPS cells
could reveal how the four genes contribute to underlying disease-causing pathomechanisms.
Finally, rescue experiments using isogenic iPS cell controls could functionally validate selected
candidate genes.
Taken together, we have identified four novel HSCR risk genes based on two patients with
L-HSCR by evaluating trio WES data and focusing on genes that harbor rare SNVs. We cor-
roborated the potential disease-relevance of three selected genes using various in vitro analyses
(Fig 5) and suggest that each of the identified variants might contribute to disease risk based
on the multifactorial origin of HSCR. Our approach represents a suitable tool identifying can-
didate genes and evaluating their disease relevance in enteric neuropathies such as HSCR. We
plan to adapt our approach to larger studies of candidate genes by up-scaling and automating
certain steps. In this way, we hope to understand the complex genetic architecture underlying
HSCR and to facilitate the development of novel therapies.
Materials and methods
Ethics statement
The parents provided written informed consent for genetic and molecular analyses, including
WES. The study was approved by the Ethical Board of the Medical Faculty of the University
Hospital Heidelberg (S509/2012).
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Candidate gene identification and selection
HSCR patients. Both HSCR patients were full-term neonates with a birthweight of 3,350 g
(patient I) and 3,470 g (patient II), and presented with long-segment aganglionosis (L-HSCR) at
least up to the colon transversum. In patient I, laparoscopic-assisted transanal endorectal pull-
through (TERPT) with simultaneous colostomy closure was performed at 14 weeks of age at the
Pediatric Surgery Clinic (University Hospital Heidelberg, Germany). Patient II underwent an assis-
ted pull-through Swenson procedure 8 months after diagnosis in another clinic. After colostomy
closure, the child suffered persistently from intestinal obstruction with severe constipation. TERPT
was repeated in Heidelberg at one year of age after persistent aganglionosis was diagnosed.
WES and variant calling. In a trio design, patients with HSCR and their non-affected
parents were analyzed by WES. The Agilent SureSelect V4 kit (Agilent Technologies, Santa
Clara, USA) was used to prepare the sequencing library. Sequencing was performed on the
Illumina HiSeq 2500 platform (Illumina, San Diego, USA) as described in the Supplementary
(S1 Text). Filtered variants for both patients (patient I: 11 genes, patient II: 14 genes) are
shown in S1 Table and S2 Table.
Transcriptomics analysis in murine tissues. For microarray profiling, embryonic regions
of interest (pre-migratory vagal NCCs at stages E8.75 and E9.5; embryonic gut at E13.5, without
stomach) were prepared and collected in 1 mL of TRIzol reagent (Thermo Fisher Scientific, Wal-
tham, USA). Embryonic tissues from each litter were pooled and three litters were analyzed per
stage. Total RNA was extracted according to the manufacturer’s instructions. For transcriptomics
analyses, 500 ng of total RNA was used for evaluation with the mouse Clariom S array (Thermo
Fisher Scientific) as described in the Supplementary (S1 Text).
Prioritization of novel HSCR candidate genes
CADD scores of single nucleotide variants were calculated using the CADD model
GRCh37-v1.4 (https://cadd.gs.washington.edu/snv), while CADD version 1.3 was installed
locally for indels (S1 Table, S2 Table, S1 Fig).
Fig 5. Study summary. HSCR candidate gene identification and validation was achieved by trio WES and various data filtering steps. Two promising candidate genes
were selected per patient (ATP7A, SREBF1 for patient I; ABCD1, PIAS2 for patient II) and were characterized using gene-specific KO cell clones. Functional analyses
revealed impaired neuronal functions thereby validating the selected genes as putative molecular players for HSCR. Figure components were kindly provided from
Microsoft Office Power Point and Servier Medical Art (https://smart.servier.com/). This work is licensed under the Creative Commons Attribution 3.0 Unported
License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA
94042, USA. The authors acknowledge the free figure access.
https://doi.org/10.1371/journal.pgen.1009106.g005
PLOS GENETICS Hirschsprung disease—A complementary study approach
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1009106 November 5, 2020 12 / 20
The relevance of filtered candidate genes in neurological diseases was assessed based on
published literature and the Genetic Association and the Disease Gene databases (https://
geneticassociationdb.nih.gov/; https://www.disgenet.org/).
Genetic evaluation of candidate genes
Available WES and whole genome sequencing (WGS) data of 767 HSCR patients [8,49] from
groups of the International HSCR Consortium (Stanislas Lyonnet, http://www.erare.eu/
financed-projects/hscr) were analyzed for the presence of rare exonic variants in the candidate
genes (ATP7A, SREBF1, ABCD1, PIAS2). Common variants/SNPs (MAF >1%) were already
excluded in individual studies. First, all variants, except for non-synonymous (missense muta-
tions, stop loss and stop gain), were removed. Next, remaining variants were compared with
variant data deposited in the gnomAD browser (population-matched comparison). Variants
were kept, if the MAF was< 1%. To assess the putative functional relevance of the filtered vari-
ants, CADD scores were calculated using the CADD model GRCh37-v1.4 (https://cadd.gs.
washington.edu/snv).
Candidate gene validation
IPA network analysis. To determine the biological context of selected candidate genes, a
network analysis was performed. A combined list of filtered WES datasets (n = 25, final candi-
date genes from both patients), ENS-relevant genes (n = 117), and HSCR-relevant genes
(n = 25) [10,16,50] was uploaded to the Ingenuity Pathway Analysis (IPA) software (Qiagen,
Venlo, The Netherlands) (S3 Table) and analyzed (S1 Text).
Screening of additional WES and WGS data. To assess the potential involvement of
selected candidate genes in ENS- and CNS-related phenotypes, clinical WES and WGS data of
approximately 15.500 cases at Baylor Genetics Laboratories (Houston, TX, USA) were
screened according to the previously applied filtering criteria. WES had been performed corre-
sponding to previously described methods [51].
GTEx database analysis. Furthermore, publicly available human brain and colon mRNA
expression profiles (GTEx database, https://www.gtexportal.org/home/) of the four selected
candidates were considered.
Protein expression analyses in murine tissues. For comparative immunofluorescence
analyses, whole murine embryos (E9.5, E10.5, E11.5, E13.5) were prepared and examined as
described in the Supplementary (S1 Text, S9 Table, S10 Table).
Protein expression analyses in human tissues. For expression analyses in human speci-
mens, formalin-fixed paraffin-embedded (FFPE) colon tissue of a fetus acardius amorphus
(25th week of gestation) was used [52]. FFPE sections were stained by immunohistochemistry
(S1 Text, S9 Table, S10 Table). A summary of the complete study approach is illustrated sche-
matically in S1 Fig.
Candidate gene characterization
Candidate genes were characterized using SHSY5Y cells (cultivated and processed as indicated
in the Supplementary (S1 Text, S8 Table, S11 Table, S12 Table)), including CRISPR/Cas9
genome editing and functional analyses.
Expression analyses of genome-edited clones. For mRNA expression analyses of
SHSY5Y clones, cells were harvested and collected in TRIzol. Total RNA was extracted using a
modified version of the RNAqueous-Micro Total RNA Isolation Kit protocol (Thermo Fisher
Scientific). Protein and mRNA expression analyses are described in the Supplementary (S1
Text, S8 Table, S9 Table, S10 Table).
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Functional in vitro assays. Migration of undifferentiated and differentiated (7+1d)
SHSY5Y cells was investigated using Boyden chamber assays as outlined in the Supplementary
(S1 Text).
Proliferation of undifferentiated and differentiated (7+1d) SHSY5Y clones was assessed
using the BrdU incorporation Kit (Roche, Basel, Switzerland). Cells were labeled with BrdU
(10 μM BrdU) for 10 h under standard cultivation conditions. The percentage of apoptotic
cells in undifferentiated and differentiated (7+7d) SHSY5Y clones was determined using the in
situ cell death detection Kit (TUNEL, Roche). In both assays, nuclei were counterstained with
Hoechst 33342 prior to mounting with Vectashield and imaged with the automated inverted
microscope DMI4000B. Ten fields of view per cell clone (20 × magnification) were analyzed
by ImageJ software 1.52i (National Institutes of Health, USA). The mean percentage of BrdU+
or TUNEL+ cells/field of view was calculated (n�3).
Statistics
Functional in vitro analyses. Statistical analyses of functional data are described in S1
Text.
Supporting information
S1 Text. Supplementary methods.
(DOCX)
S1 Data. Supplementary results.
(DOCX)
S1 Table. Filtered WES data of patient I. HGVS nomenclature of variants was verified using
the batch validation tool Mutalyzer (https://mutalyzer.nl). CADD scores were calculated using
the CADD model GRCh37-v1.4 (https://cadd.gs.washington.edu/snv). �For indels, CADD ver-
sion 1.3 was locally installed. Genes lettered in grey had CADD scores < 13 and were excluded
from further analyses. Grey columns were not followed up as no neurological phenotype could
be associated to the respective candidate gene after a database (https://geneticassociationdb.
nih.gov/; https://www.disgenet.org/) and literature search. Selected candidate genes are
highlighted in bold letters. n.a.: not annotated, comp.: compound, AD: Alzheimer disease,
ALS: Amyotrophic lateral sclerosis, ID: Intellectual disability, MS: Multiple sclerosis, PD: Par-
kinson disease.
(PDF)
S2 Table. Filtered WES data of patient II. HGVS nomenclature of variants was verified using
the batch validation tool Mutalyzer (https://mutalyzer.nl). CADD scores were calculated using
the CADD model GRCh37-v1.4 (https://cadd.gs.washington.edu/snv). �For indels, CADD ver-
sion 1.3 was installed locally. Genes lettered in grey had CADD scores < 13 and were excluded
from further analyses. Grey columns were not followed up as no neurological phenotype could
be associated to the respective candidate gene after a database (https://geneticassociationdb.
nih.gov/; https://www.disgenet.org/) and literature search. Selected candidate genes are
highlighted in bold letters. n.a.: not annotated, comp.: compound, AD: Alzheimer disease,
ASD: Autism spectrum disorder, BP: Bipolar disorder, ID: Intellectual disability, PD: Parkin-
son disease, X-ALD: X-linked adrenoleukodystrophy.
(PDF)
S3 Table. IPA input (ENS-relevant and HSCR risk genes).
(PDF)
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S4 Table. Rare candidate-specific variants identified in further patients with HSCR. HGVS
nomenclature of variants was verified using the batch validation tool Mutalyzer (https://
mutalyzer.nl). CADD scores were calculated using the CADD model GRCh37-v1.4 (https://
cadd.gs.washington.edu/snv). For gnomAD comparisons, population-matched control
cohorts were used (non-Finnish European, 284 patients [8]; East Asian, 443 patients [49]). n.
a.: not annotated, EA: South-Asian, EUR: European. Gene isoforms: ATP7A NM_001282224;
SREBF1 NM_004176; ABCD1 NM_000033; PIAS2 NM_004671. �patient with feeding issues
and severe developmental delay.
(PDF)
S5 Table. Rare candidate-specific variants identified from clinical exome or genome
sequencing data sets. HGVS nomenclature of variants was verified using the batch validation
tool Mutalyzer (https://mutalyzer.nl). CADD scores were calculated using the CADD model
GRCh37-v1.4 (https://cadd.gs.washington.edu/snv). For gnomAD comparisons control data
were used. n.a.: not annotated. Gene isoforms: ATP7A NM_000052; SREBF1 NM_004176;
#NM_001005291, ABCD1 NM_000033; PIAS2 NM_004671; §NM_173206.
(PDF)
S6 Table. Results of protein expression analyses in murine embryonic tissues. Green indi-
cates partial co-expression of both antigens or immunofluorescence signals in close spatial
proximity to each other. Red indicates no overlap in respective antigen signals.
(PDF)




S9 Table. Primary antibodies.
(PDF)




S12 Table. Oligonucleotides used for off-target analysis.
(PDF)
S13 Table. Raw data for figures.
(XLSX)
S1 Fig. Components of our comparative study pipeline. Flowchart showing the WES analy-
sis approach and the subsequent steps involved in candidate gene A) identification and selec-
tion, B) prioritization as well as C) validation. Technical details and cut offs are given. MAF:
Minor allele frequency, comp.: compound.
(PDF)
S2 Fig. Variant validation in selected candidate genes by Sanger sequencing. Four colored
chromatograms are shown for all members of family I (A) and family II (B). In case of hetero-
zygous states, ambiguity codes are given.
(PDF)
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S3 Fig. Protein expression analyses of candidates in murine embryonic and human fetal
tissue sections. (A) Expression analyses of each candidate with the NCC marker Sox10
(green) in murine embryos of stage E9.5 are shown. Sox10+ cells in close proximity to the
neck are displayed. Cranial and caudal positions are indicated (Atp7a (A'), Srebf1 (A"), Abcd1
(A"'), Pias2 (A""), all in red). Immunofluorescence signals in close spatial proximity suggesting
co-expression, are indicated by white arrowheads. (B) Triple staining in the developing midgut
at E13.5 reveals expression of all candidates within or in close spatial proximity to immature
neurons (Tubb3 (green)) and immature smooth muscle cells (Sma (cyan)); (Atp7a (B'), Srebf1
(B"), Abcd1 (B"'), Pias2 (B""), all in red) (white arrowheads). The gut lumen is highlighted. (A,
B) Bottom images show magnifications of the areas highlighted in the top images. Nuclei were
counterstained with Hoechst 33342 (blue). Scale bars: 50 μm. (C) Immunohistochemistry anal-
yses in human fetal colon sections show candidate protein expression in enteric ganglia
(marked by a red arrowhead) except for ABCD1 (C"'). Bottom images illustrate the gut epithe-
lial layer where candidates are expressed in enterocytes (ATP7A (C'), SREBF1 (C"), PIAS2
(C""), all in brown). Nuclei were counterstained with hematoxylin (blue). Scale bars: 20 μm.
(PDF)
S4 Fig. RNA expression of selected candidates in human fetal colon tissue. Published RNA
sequencing data [2] were evaluated for the expression of selected candidates. Bar chart shows
reads per kilobase of exon model per million mapped reads (RPKM) in human fetal hindgut
specimens of embryonic week (EW) 12, 14, and 16.
(PDF)
S5 Fig. CRISPR/Cas9 gene mediated KO of RET and candidate genes. (A'–D') Gene-specific
sgRNAs were designed against marked exons. Cas9-mediated double-strand breaks were
repaired by NHEJ causing homozygous or compound heterozygous genome modifications at
the respective positions, as verified by Sanger sequencing. Four color chromatograms are
shown for the genes (RET (A'), ATP7A (B'), SREBF1 (C'), ABCD1 (D')). Genome editing for
PIAS2 did not work. PAM sites are underscored. Putative Cas9-cutting sites are marked by red
arrowheads. (A"–D") Knockout (KO) on protein level was validated by Western blot analyses
using different protein lysates as internal controls (HEK293TN cells transiently transfected
with a gene-specific, tagged overexpression construct, SHSY5Y cells, mock control cells) (RET
(A"), ATP7A (B"), SREBF1 (C"), ABCD1 (D")). GAPDH was used as a loading control. Pre-
dicted protein sizes are annotated. Images show modified blots as individual lanes of respective
blots were rearranged if necessary. FL: full length, MAT: mature.
(PDF)
S6 Fig. qRT PCR expression profiling of selected cell markers in differentiating cell clones.
Gene expression profiles of different cell fate markers such as P75NTR and NES (neuronal pro-
genitor markers) as well as UCHL1 and ASCL1 (advanced neuronal cell fate markers) in differ-
entiating genome-edited cell clones by qRT PCR analysis. (n = 3, mean + standard error of
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